Nrg-Hn005- Randomized Phase II And Phase III Studies Of Individualized Treatment For Nasopharyngeal Carcinoma Based On Biomarker Epstein Barr Virus (Ebv) Deoxyribonucleic Acid (Dna)
Posted Date: Nov 7, 2019
- Investigator: Vinita Takiar
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The goal of this study is to demonstrate non-inferiority in terms of progression-free survival (PFS) of concurrent reduced-dose radiation therapy (RT) with cisplatin or concurrent reduced-dose radiation therapy with nivolumab to the current standard of care
Criteria:
To Be Eligible: Diagnosed With Scc Of The Oropharynx, At Least 18 Yrs Of Age, Nonpregnant/Nonbreastfeeding, No Recurrent Disease, No Prior Metastatic Disease Within 3 Years, No Prior Treatment For Study Cancer, No Severe, Active Co-Morbitity
Keywords:
Head And Neck Cancer, Nasopharyngeal
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com